---
schema_version: "secwatch.filing_event.v1"
accession: "0001764013-23-000063"
form_type: "8-K"
ticker: "IMVT"
cik: "0001764013"
company_name: "Immunovant, Inc."
filed_at: "2023-05-22T23:59:59+00:00"
generated_at: "2026-06-14T18:23:53.046701+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Immunovant reports FY2023 net loss $211M; IMVT-1402 IND cleared, Phase 1 started

## Summary
- Net loss of $59.4M ($0.46/share) for Q4 FY2023 vs $47.2M ($0.41) a year ago.
- Full-year net loss $211.0M ($1.71/share) vs $156.7M ($1.43); cash $376.5M funding into H2 2025.
- R&D expenses rose 61% YoY to $160.3M, driven by batoclimab and IMVT-1402 programs.
- FDA IND and MEDSAFE CTA cleared for IMVT-1402; Phase 1 trial enrolling in New Zealand.
- Initial Phase 1 data from single-ascending dose expected Aug/Sep 2023; MAD data Oct/Nov 2023.

## SEC filing metadata
- accession: 0001764013-23-000063
- form_type: 8-K
- ticker: IMVT
- cik: 0001764013
- company_name: Immunovant, Inc.
- filed_at: 2023-05-22T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1764013/000176401323000063/0001764013-23-000063-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1764013/000176401323000063/imvt-20230522.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001764013-23-000063
- JSON: https://secwatch.observer/filing/0001764013-23-000063.json
- Plain text: https://secwatch.observer/filing/0001764013-23-000063.txt

## Key facts
- Earnings Releases
  Immunovant, Inc. reported the three months ended March 31, 2023 results: net income $59.4 million, EPS $0.46 per common share.
  - Period: the three months ended March 31, 2023
  - Net income: $59.4 million
  - EPS: $0.46 per common share
  - Result: reported results
  source text: Net loss was $59.4 million ($0.46 per common share) for the three months ended March 31, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1764013/000176401323000063/0001764013-23-000063-index.htm
- Earnings Releases
  Immunovant, Inc. reported the fiscal year ended March 31, 2023 results: net income $211.0 million, EPS $1.71 per common share.
  - Period: the fiscal year ended March 31, 2023
  - Net income: $211.0 million
  - EPS: $1.71 per common share
  - Result: reported results
  source text: Net loss was $211.0 million ($1.71 per common share) for the fiscal year ended March 31, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1764013/000176401323000063/0001764013-23-000063-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.